32 news items
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
ATNM
BMY
BPTH
17 Jun 24
and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY
13 Jun 24
the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
BMY
4 Jun 24
contains "forward-looking statements" within the meaning of the Private Securities Litigation
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY
3 Jun 24
the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
BMY
1 Jun 24
contains "forward-looking statements" within the meaning of the Private Securities Litigation
3evmmyqx8cfkedog6kt7 9yeo4rtvtmmmhmph04stzu0
BMY
30 May 24
contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding
xzvyctrpby pgg6egdqdj
BMY
23 May 24
the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization
oo66oe0qeqlnze4cx3tnsce79yj78cnt2h0v6g7lgv5ssmw1vt29ej6
BMY
16 May 24
of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical
acrb99ly8mshuf6047d4clpxr2r9iftrzm18bss1j
BMY
15 May 24
contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding
cvs0dqt3ij1imuw
BMY
10 May 24
contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things
80a6uziuvdihnq ks5
BMY
26 Apr 24
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995
76f55g92vwy78mwk7yqubtzubibu7qu52gw7oalxc9tdh8bwv
BMY
25 Apr 24
to the items above, the decrease was also due to lower litigation and other settlement income. The company reported on a non-GAAP basis net loss
gj55s
ABBV
ATNM
AZN
19 Apr 24
not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking
8u9bo2
ATNM
AZN
BMY
18 Apr 24
Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects
8fvo7ofn6z53ixtcubm191rn52ly
ATNM
AZN
BMY
17 Apr 24
investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act